CN105223363A - Detect method and the monoclonal antibody thereof of campylobacter jejuni - Google Patents
Detect method and the monoclonal antibody thereof of campylobacter jejuni Download PDFInfo
- Publication number
- CN105223363A CN105223363A CN201510573715.0A CN201510573715A CN105223363A CN 105223363 A CN105223363 A CN 105223363A CN 201510573715 A CN201510573715 A CN 201510573715A CN 105223363 A CN105223363 A CN 105223363A
- Authority
- CN
- China
- Prior art keywords
- antibody
- campylobacter jejuni
- monoclonal antibody
- 4c9e1g7h3
- cgmccno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000589875 Campylobacter jejuni Species 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 47
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 38
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 238000012360 testing method Methods 0.000 claims description 32
- 239000007790 solid phase Substances 0.000 claims description 20
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 17
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000006911 enzymatic reaction Methods 0.000 claims description 8
- 241000589876 Campylobacter Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 6
- 239000000523 sample Substances 0.000 description 28
- 239000007788 liquid Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 239000000047 product Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 230000037029 cross reaction Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229940005654 nitrite ion Drugs 0.000 description 5
- 241000589562 Brucella Species 0.000 description 4
- 206010008631 Cholera Diseases 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001630 jejunum Anatomy 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 3
- 241001148129 Yersinia ruckeri Species 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 3
- 244000078673 foodborn pathogen Species 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010061393 typhus Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- -1 urase Substances 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- WBODDOZXDKQEFS-UHFFFAOYSA-N 1,2,3,4-tetramethyl-5-phenylbenzene Chemical group CC1=C(C)C(C)=CC(C=2C=CC=CC=2)=C1C WBODDOZXDKQEFS-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- GEWYFWXMYWWLHW-UHFFFAOYSA-N azanium;octanoate Chemical compound [NH4+].CCCCCCCC([O-])=O GEWYFWXMYWWLHW-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56922—Campylobacter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to microorganism detection field.Specifically, the present invention relates to a kind of detect campylobacter jejuni method, for two strains of the method by the monoclonal antibody of the anti-campylobacter jejuni produced with monoclonal antibody preparation process, this monoclonal antibody can be combined with campylobacter jejuni specifically.Is it by mouse hybridoma cell system 3G2D8H3G9, CGMCC? No.8766 or 4C9E1G7H3, CGMCC? No.8457 produced.Present invention also offers the purposes of the monoclonal antibody of anti-campylobacter jejuni.
Description
Technical field
The invention belongs to microorganism detection field.Specifically, the present invention relates to a kind of anti-campylobacter jejuni monoclonal antibody, produce the purposes of the hybridoma of this monoclonal antibody and the monoclonal antibody of anti-campylobacter jejuni.
Background technology
Campylobacter jejuni (campylobacterjejunienteritis) is that Butzler in 1973 etc. separate in Feces of Patients With Diarrhea, has been familiar with one of its Main Pathogenic Bacteria for mankind's diarrhoea at present.The incidence of disease of campylobacter jejuni enteritis exceedes bacillary dysentery in developed country, and in developing country, the incidence of disease is almost equal to bacillary dysentery.This bacterium is as important food-borne pathogens, along with food enter enteron aisle after containing breeding rapidly under micro amount of oxygen environment, main infringement jejunum, ileum and colon, invasion and attack intestinal mucosa, cause hyperemia and heamorrhagic lesions, observe some bacterial strain in recent years and can produce similar cholera enterotoxin, cause liquid secretion in enteric cavity to increase.
The detection of current campylobacter jejuni depends on the biochemical identification of GB defined, and its shortcoming is that complex operation, sense cycle are longer, cannot adapt to a large amount of sample examinations.Immunology detection is quick, accurate, the most stable quick detection means occurred in recent years; but there is no the quick testing product that can apply to detect practice both at home and abroad at present; this patent is detect target with campylobacter jejuni, and technology required for protection relates to the quick testing product of campylobacter jejuni.
Summary of the invention
The object of this invention is to provide a kind of method of vitro detection vibrio parahemolyticus.
Another object of the present invention is to provide two strains for said method by the monoclonal antibody that can be incorporated into the different antigen site of vibrio parahemolyticus specifically produced with monoclonal antibody preparation process.
Another object of the present invention is to provide the hybridoma producing said monoclonal antibody.
A first aspect of the present invention there is provided a kind of method of vitro detection campylobacter jejuni, and described method is used for non-diseases diagnostic purpose, comprises the following steps:
A testing sample application of sample is caught the solid phase carrier of antibody in being coated with by (), thus the seizure antibody of the campylobacter jejuni in testing sample on solid phase carrier is combined, and forms the solid phase carrier with " campylobacter jejuni-seizure antibody " binary complex; Described seizure antibody is the monoclonal antibody 3G2D8H3G9 being incorporated into campylobacter jejuni specifically, and described monoclonal antibody 3G2D8H3G9 is produced by mouse hybridoma cell system 3G2D8H3G9, CGMCCNo.8766;
B () will detect the solid phase carrier that antibody application of sample obtains in (a), thus form the solid phase carrier with " detecting antibody-campylobacter jejuni-seizure antibody " ternary complex; Described detection antibody is the monoclonal antibody 4C9E1G7H3 being incorporated into campylobacter jejuni specifically, described monoclonal antibody 4C9E1G7H3 is by mouse hybridoma cell system 4C9E1G7H3, CGMCCNo.8457 produces, and described monoclonal antibody 4C9E1G7H3 carries a detectable; With
C () detects the detectable in ternary complex, thus whether and the amount existed the existence determining testing sample jejuni.
In a preference, described solid phase carrier is enzyme reaction plate.
In another preference, described detectable is horseradish peroxidase.
A second aspect of the present invention there is provided a kind of immunoglobulin (Ig), and it is the monoclonal antibody being incorporated into campylobacter jejuni specifically, and it is by mouse hybridoma cell system 3G2D8H3G9, and CGMCCNo.8766 produced.
A third aspect of the present invention there is provided a kind of hybridoma producing monoclonal antibody, and it is mouse hybridoma cell system 3G2D8H3G9, CGMCCNo.8766.
A fourth aspect of the present invention there is provided the purposes of above-mentioned immunoglobulin (Ig), and it is used to detect campylobacter jejuni, and described purposes is used for non-diseases diagnostic purpose.
A fifth aspect of the present invention there is provided a kind of immunoglobulin (Ig), and it is the monoclonal antibody being incorporated into campylobacter jejuni specifically, and it is by mouse hybridoma cell system 4C9E1G7H3, and CGMCCNo.8457 produced.
A sixth aspect of the present invention there is provided a kind of hybridoma producing monoclonal antibody, and it is mouse hybridoma cell system 4C9E1G7H3, CGMCCNo.8457.
Present invention also offers the purposes of above-mentioned immunoglobulin (Ig), it is used to detect campylobacter jejuni, and described purposes is used for non-diseases diagnostic purpose.
The details of various aspects of the present invention is able to detailed description by chapters and sections subsequently.By hereafter and the description of claim, feature of the present invention, object and advantage will be more obvious.
Accompanying drawing explanation
The SDS-PAGE electrophoretogram of Fig. 1 monoclonal antibody of the present invention
Lane1：4C9E1G7H3，Lane3：3G2D8H3G9。
Embodiment
The research of the present inventor shows, using campylobacter jejuni as immunogene, immunity Balb/c mouse, separation and purification obtains anti-campylobacter jejuni monoclonal antibody 4C9E1G7H3 and 3G2D8H3G9, its antibody titer can reach 1:100000, its can specificity, be combined with campylobacter jejuni efficiently, with singly increase Liszt, 91 kinds of bacteriums (strain) all no cross reactions such as hog cholera sramana, mouse typhus sramana, enteritis sramana, Fu Shi will are congratulated, Song Nei Shi will is congratulated, Boydii will is congratulated, large intestine O157:H7, small intestine Yersinia ruckeri.
The invention provides anti-campylobacter jejuni monoclonal antibody.Anti-campylobacter jejuni monoclonal antibody of the present invention can utilize mouse hybridoma cell system 4C9E1G7H3 (CGMCCNo.8457) or 3G2D8H3G9 (CGMCCNo.8766) secretion to produce.The present invention includes the monoclonal antibody of the corresponding amino acid sequence with anti-campylobacter jejuni monoclonal antibody 4C9E1G7H3 and 3G2D8H3G9, and there is other protein of these chains or protein conjugate and fusion expressed product.Particularly, the present invention includes and have containing hypervariable region (complementary determining region, any protein of light chain CDR) and heavy chain or protein conjugate and fusion expressed product (i.e. immune conjugate and fusion expressed product), as long as this hypervariable region is identical with the hypervariable region of heavy chain with light chain of the present invention or at least 90% homology, preferably at least 95% homology.As is known to the person skilled in the art, immune conjugate and fusion expressed product comprise: that medicine, toxin, cell factor (cytokine), radioactive nuclide, enzyme and other diagnosis or treatment molecule are combined with anti-campylobacter jejuni monoclonal antibody or its fragment and the conjugate that formed.The present invention also comprises the cell surface marker thing or antigen that are combined with anti-campylobacter jejuni monoclonal antibody or its fragment.
For anti-campylobacter jejuni monoclonal antibody heavy of the present invention and sequence of light chain, can measure by conventional method.Hypervariable region or complementary determining region (complementaritydeterminingregion, the CDR) of anti-campylobacter jejuni monoclonal antibody V chain are interesting especially, because relate to conjugated antigen at least partly in them.Therefore, the present invention includes those and there is the band light chain immunoglobulin of CDR and the molecule of weight chain variable chain, as long as its CDR and anti-campylobacter jejuni monoclonal antibody CDR has the homology of more than 90% (preferably more than 95%).The present invention not only comprises complete monoclonal antibody, also comprises and has immunocompetent antibody fragment, as Fab or (Fab ')
2fragment; Heavy chain of antibody; Light chain of antibody.
Present invention also offers the DNA molecular of above-mentioned immunoglobulin (Ig) or its fragment.The sequence of these DNA moleculars can use routine techniques, utilizes hybridoma cell line 4C9E1G7H3 (CGMCCNo.8457) or 3G2D8H3G9 (CGMCCNo.8766) to obtain.In addition, also the coded sequence of light chain and heavy chain can be merged, form single-chain antibody.
Once obtain relevant sequence, just relevant sequence can be obtained in large quantity with recombination method.This is normally cloned into carrier, then proceeds to cell, is then separated from the host cell after propagation by conventional method and obtains relevant sequence.
In addition, also relevant sequence can be synthesized, when especially fragment length is shorter by the method for Prof. Du Yucang.Usually, by first synthesizing multiple small fragment, and then carry out connect can obtain the very long fragment of sequence.
At present, the DNA sequence dna of code book invention albumen (or its fragment, or derivatives thereof) can be obtained completely by chemosynthesis.Then this DNA sequence dna can be introduced in the various existing DNA molecular (or as carrier) that in this area, oneself knows and cell.In addition, also by chemosynthesis, sudden change is introduced in protein sequence of the present invention.
The invention still further relates to the carrier comprising above-mentioned suitable DNA sequence dna and suitable promoter or control sequence.These carriers may be used for transforming suitable host cell, with can marking protein.
Host cell can be prokaryotic, as bacterial cell; Or the eukaryotic such as low, as yeast cells; Or higher eucaryotic cells, as mammalian cell.
Can carry out with routine techniques well known to those skilled in the art with recombinant DNA transformed host cell.When host be prokaryotes as Enterohemorrhagic E.coli time, the competent cell that can absorb DNA can be gathered in the crops at exponential growth after date, uses CaC1
2method process, step used is well-known in this area.Another kind method uses MgC1
2.If needed, transform and also can be undertaken by the method for electroporation.When host is eucaryote, following DNA transfection method can be used: calcium phosphate precipitation, conventional mechanical methods as microinjection, electroporation, liposome packaging etc.
The transformant obtained can be cultivated by conventional method, expresses the polypeptide of coded by said gene of the present invention.According to host cell used, nutrient culture media used in cultivation can be selected from various conventional medium.Cultivate under the condition being suitable for host cell growth.When after host cell growth to suitable cell density, the promoter selected with the induction of suitable method (as temperature transition or chemical induction), cultivates a period of time again by cell.
Recombinant polypeptide in the above methods can be expressed or be secreted into extracellular in cell or on cell membrane.If needed, can utilize its physics, the albumen of being recombinated by various separation method abstraction and purification with other characteristic of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation process, combination by protein precipitant process (salting-out method), centrifugal, the broken bacterium of infiltration, ultrasonic process, ultracentrifugation, sieve chromatography (gel filtration), adsorption chromatography, ion-exchange chromatography, high performance liquid chroma-tography (HPLC) and other various liquid chromatography (LC) technology and these methods.
Anti-campylobacter jejuni monoclonal antibody of the present invention, its height of tiring (can 1:100000 be reached), campylobacter jejuni can be detected specifically, efficiently, with singly increase Liszt, 91 kinds of bacteriums (strain) all no cross reactions such as hog cholera sramana, mouse typhus sramana, enteritis sramana, Fu Shi will are congratulated, Song Nei Shi will is congratulated, Boydii will is congratulated, large intestine O157:H7, small intestine Yersinia ruckeri,, this is maximum innovative point of the present invention.Said monoclonal antibody 4C9E1G7H3 can use horseradish peroxidase, alkaline phosphatase, nanogold particle to mark, and uses in specific manner as detecting antibody.Said monoclonal antibody 3G2D8H3G9, in various detection is used, can use as catching antibody in specific manner.
Detection kit
The present inventor is through to study widely and test, be surprised to find that, after the anti-campylobacter jejuni monoclonal antibody adopting mouse hybridoma cell system 3G2D8H3G9 (CGMCCNo.8766) to produce is as seizure antibody capture campylobacter jejuni, the anti-campylobacter jejuni monoclonal antibody produced by mouse hybridoma cell system 4C9E1G7H3 (CGMCCNo.8457) marked with detectable label is again as detection antibody, extremely effectively can be incorporated into campylobacter jejuni, thus detect campylobacter jejuni in high sensitivity by double-antibody method.
As used herein, described " sample " refers to the materials such as food, human and animal excreta, vomitus, includes but not limited to: the enrichment liquid of serum, blood plasma, ight soil, food etc.Preferably, described sample is food.
As used herein, described " seizure antibody ", " coated antibody ", " first antibody " and " primary antibodie " is used interchangeably, all refer to the described monoclonal antibody that can be incorporated into campylobacter jejuni specifically, it is produced by mouse hybridoma cell system 3G2D8H3G9, CGMCCNo.8766.
Described seizure antibody can be coated on solid phase carrier.The present invention has no particular limits adopted solid phase carrier, if its can with seizure antibody phase coupling (connection).Such as, described solid phase carrier is enzyme reaction plate.
As used herein, described " detection antibody ", " second antibody ", " enzyme labelled antibody " was used interchangeably with " two resist ", all refer to can specific binding in another strain monoclonal antibody of campylobacter jejuni, it is produced by mouse hybridoma cell system 4C9E1G7H3, CGMCCNo.8457.
As used herein, described " specificity " refers to that antibody can only be incorporated into campylobacter jejuni; More particularly, refer to that those can be combined with campylobacter jejuni but nonrecognition and be incorporated into the antibody of other non related antigen molecule.
The present inventor and then according to double antibodies sandwich ratio juris, has prepared a kind of enzyme linked immunological kit that can be used for detecting sample jejuni.The way of double-antibody method routine is that seizure antibody is fixed on carrier, then antibody and antigen-reactive is caught, after washing, (described detection antibody carries detectable with detection antibody response again, or can be combined with the material carrying detectable), finally carry out chemiluminescence or enzyme connection chromogenic reaction detection signal.Further, relative to the competition law of monoclonal antibody body, the mensuration effect of double antibody sandwich method is more excellent, only needs little sample size when thus measuring.So adopt double antibody sandwich method no matter to have more advantage in sensitivity, degree of accuracy, accuracy, specificity and stability.
Specifically, enzyme linked immunological kit of the present invention contains:
(a) enzyme reaction plate, described enzyme reaction plate is coated with the anti-campylobacter jejuni monoclonal antibody 3G2D8H3G9 as catching antibody, described anti-campylobacter jejuni monoclonal antibody is produced by mouse hybridoma cell system 3G2D8H3G9, CGMCCNo.8766;
B () container a, the anti-campylobacter jejuni monoclonal antibody 4C9E1G7H3 as detecting antibody is housed in described container a, and described anti-campylobacter jejuni monoclonal antibody is produced by mouse hybridoma cell system 4C9E1G7H3, CGMCCNo.8457.
As optimal way of the present invention, described detection antibody is with detectable label.
As used herein, described " detectable label " refers to that whether and the mark of the amount existed existence for determining detected sample jejuni.Determining seizure antibody that kit of the present invention adopts and/or after detecting antibody, this area can adopted conventional for being combined with detection antibody the various labels carrying out detecting.The present invention has no particular limits adopted label, as long as can be combined with described detection antibody, and can indicate exactly after appropriate processing the existence of detected sample jejuni whether and the label of amount be all available.Described label directly can be arranged at and detect on antibody; Or described label also can be arranged on the antiantibody of the anti-detection antibody of specificity, those skilled in the art according to the kind of adopted antibody and characteristic, can select suitable label.Such as, described label can be selected from: horseradish peroxidase (HRP), alkaline phosphatase vinegar enzyme (AP), glucose oxidase, beta-D-galactosidase, urase, hydrogen peroxidase or glucoamylase.
When adopting some enzyme marker as implied above, also need the substrate adopting some to be combined with corresponding enzyme, thus report label by modes such as colour developings there is situation or amount.As used herein, described " substrate corresponding with label " refers to and can be labeled thing institute catalyzed coloration, for showing the identification signal detecting antibody and campylobacter jejuni and occur to combine.Described substrate is such as: for adjacent benzene two limb (OPD), tetramethyl biphenyl limb (TMB), the ABTS of horseradish peroxidase; For p-nitrophenyl phosphoric acid vinegar (p-nitrophenylphosphate, p-NPP) etc. of alkaline phosphatase.Those skilled in the art according to the kind of adopted label and characteristic, can select suitable substrate.
As optimal way of the present invention, described detection antibody is directly connected with label.More preferably, described label is HRP.With detect antibody with biotin labeling, react after compare with streptavidin HRP reacting phase again, directly detection antibody on mark HRP, reaction terminate after directly add substrate colour developing more simple and convenient.
In order to obtain quantitative result, the standard items knowing multiple campylobacter jejunis of concentration containing oneself can also be set in testing process.Method to set up for standard items can adopt conventional method.
In order to eliminate false positive and false negative, also Quality Control (contrast) can be set in testing process.As optimal way of the present invention, described positive control is the campylobacter jejuni bacterium liquid of deactivation, and described negative control is the brucella broth (Brucellabroth) of sterilizing.
In addition, in order to make kit of the present invention more convenient when detecting, preferably some other auxiliary reagent is also comprised in described kit, described auxiliary reagent is conventional some reagent used in ELISA kit, and the characteristic of these reagent and their compound method are all well-known to those skilled in the art.Described reagent is (but being not limited to) such as: developer, cleansing solution, stop buffer, enrichment liquid, dilution.
In addition, in described kit, also operation instructions can be comprised, for illustration of the using method of the reagent wherein loaded.
Cleaning Principle and the beneficial effect of enzyme linked immunological kit of the present invention are as follows:
What kit of the present invention adopted is DASELISA immunization.Anti-campylobacter jejuni monoclonal antibody (seizure antibody) is had when pre-coated on enzyme reaction plate, after adding sample solution or standard items, add with the anti-campylobacter jejuni monoclonal antibody of detectable label another strain as horseradish peroxidase (detection antibody) again, the campylobacter jejuni existed in sample or standard items will combine with seizure antibody enzyme reaction plate wrapping quilt, after detection antibody to be added, " antibody-antigen-enzyme labelled antibody " compound can be formed, yellow substance can be formed after TMB (tetramethyl benzidine) colour developing, thus can judgement sample jejuni existence whether and the amount existed.
Under 450nm, absorbance is measured by microplate reader.Negative control≤0.1, positive control >=0.3, experimental result is effective, otherwise result be judged to be invalid; During detect aperture OD value >=0.2, be judged to be the positive; When detect aperture OD value is between 0.1-0.2, be judged to be the weak positive; Detect aperture OD value≤0.1 is judged to be feminine gender.
Test shows, campylobacter jejuni enzyme linked immunological kit of the present invention, has higher sensitivity and accuracy.Between plate, error is less than 5%, and in plate, CV is less than 3%.With singly increase Liszt, hog cholera sramana, mouse typhus sramana, enteritis sramana, Fu Shi will is congratulated, Song Nei Shi will is congratulated, Boydii will is congratulated, Escherichia coli O 157: H7, small intestine Yersinia ruckeri etc. amount to 91 kinds of equal no cross reactions of pathogenetic bacteria, this is maximum innovative point of the present invention.
In a word, kit of the present invention requires low, easy and simple to handle to the pre-treatment of sample, and detection limit is 10
5cfu/ml, specificity and good stability, and all there is no cross reaction with most of food-borne pathogens.
Detection method
Present invention also offers a kind of method utilizing kit vitro detection campylobacter jejuni of the present invention, comprise the following steps:
A testing sample application of sample is caught the solid phase carrier of antibody in being coated with by (), thus the seizure antibody of the campylobacter jejuni in testing sample on solid phase carrier is combined, and forms the solid phase carrier with " campylobacter jejuni-seizure antibody " binary complex; Described seizure antibody is the monoclonal antibody 3G2D8H3G9 being incorporated into campylobacter jejuni specifically, and described monoclonal antibody 3G2D8H3G9 is produced by mouse hybridoma cell system 3G2D8H3G9, CGMCCNo.8766;
B () will detect the solid phase carrier that antibody application of sample obtains in (a), thus form the solid phase carrier with " detecting antibody-campylobacter jejuni-seizure antibody " ternary complex; Described detection antibody is the monoclonal antibody 4C9E1G7H3 being incorporated into campylobacter jejuni specifically, described monoclonal antibody 4C9E1G7H3 is by mouse hybridoma cell system 4C9E1G7H3, CGMCCNo.8457 produces, and described monoclonal antibody 4C9E1G7H3 carries a detectable; With
C () detects the detectable in ternary complex, thus whether and the amount existed the existence determining detected sample jejuni.
As a kind of optimal way of the present invention, the method quantitatively detecting campylobacter jejuni is specific as follows:
(I) antigen-antibody reaction: be coated on porous plate by seizure antibody of the present invention, adds the standard items of variable concentrations, quality-control product (optional) afterwards respectively in the micropore of porous plate, or testing sample;
(II) integrated enzyme reaction: antibody (being provided with label) solution will be detected and add each hole, and vibrate, hatch, wash;
(III) chromogenic reaction: every hole adds substrate, developer corresponding to label, and hatch, every hole adds reaction terminating liquid, terminates reaction:
(IV) microplate reader measures OD value:
(V) result calculates:
A) production standard curve: with campylobacter jejuni standard concentration for horizontal ordinate, it is ordinate that standard items measure OD value, makes typical curve;
B) quality-control product concentration (optional) is passed judgment on: according to the OD value of quality-control product, read corresponding concentration value from typical curve; When quality-control product mensuration concentration value is in given range, this time measures effectively;
C) calculate testing sample concentration: when typical curve and quality-control product are all determined effective, calculate the jejunum campylobacter bacteria concentration of testing sample according to the OD value of sample to be tested from typical curve.
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usual conveniently condition is as people such as Sambrook, molecular cloning: laboratory manual (NewYork:ColdSpringHarborLaboratoryPress, 1989) condition described in, or according to the condition that manufacturer advises.
The preparation of the anti-campylobacter jejuni monoclonal antibody 4C9E1G7H3 and 3G2D8H3G9 of embodiment 1.
One, the preparation of immunogene and positive criteria product
Campylobacter jejuni (CICCNo.22937) is seeded on brucella broth, and 37 DEG C, 150r/min vibration anaerobic condition cultivation 17h, counting, adds 0.3% formalin room temperature deactivation 1 day.Campylobacter jejuni (CICCNo.22937) concentration to 5 × 10 are adjusted with physiological saline
9cfu/ml is as immunogene; Adjusting concentration with physiological saline is 10
8cfu/ml is as positive control standard items, and brucella broth is negative control standard items.
Two, the preparation of monoclonal antibody
1, animal used as test: select 38 week ages, about body weight 20g, female Balb/c mouse are animal used as test.
2, immunization method: every mouse peritoneal injection 0.2ml immunogene, at interval of 2 weeks with same dosage booster shots once.
3, take a blood sample: from tail vein blood sampling after 3 booster immunizations, adopt indirect non-competing euzymelinked immunosorbent assay (ELISA) to measure antiserum titre.Wait to tire and no longer rise, lumbar injection same amount immunogene, conventionally carried out Fusion of Cells after 3 days.
4, Fusion of Cells: get that immune mouse spleen cell and SP2/0 myeloma cell are conventional under 50%PEG effect merges, is inoculated in 96 well culture plates respectively, is placed in 37 DEG C, 5%CO
2incubator is cultivated.
5, filtering hybridoma: adopt indirect non-competing euzymelinked immunosorbent assay (ELISA), the hybridoma in screening strong positive hole, transfers them to 24 well culture plates.
6, clone cultivates and antibody preparation: carry out colonized culture with limiting dilution assay.When Growth of Cells is to when to be paved with at the bottom of hole 1/10, then detect with same method, strong positive hole is cloned, 3-4 time so repeatedly, until positive rate reaches 100% again.Hybridoma is expanded and cultivates, be injected in through the pretreated Balb/c mouse peritoneal of paraffin oil, every 2 × 10
6individual hybridoma, 7 ~ 10 days mouse web portion protuberances, living body puncture extracts ascites.
Three, monoclonal antibody-purified and qualification
After ascites is first slightly carried with caprylic acid-ammonium, then purify with ProteinGSepharose affinity chromatography; Antibody after purifying measures with indirect elisa method and tires (see table 1) after doubling dilution; Use SDS-PAGE purity assay again, 5% spacer gel, 10% separation gel, 120V voltage, bottom electrophoresis to glue, gel Coomassie Brilliant Blue dyes, Labworks image acquisition and analysis software observations (see Fig. 1) after decolouring.
Table 1. liang strain antibody titer measurement result (OD
450)
The CHARACTERISTICS IDENTIFICATION of embodiment 2. monoclonal antibody 4C9E1G7H3 and 3G2D8H3G9
One, monoclonal antibody subgroup identification
1, antigen coated: with 0.01MPBS bag by goat against murine two anti-igg+A+M, every hole 50 μ l, 4 DEG C of bags are spent the night, and discard liquid in hole next day, wash plate 3 times.
2, close: every hole adds 1%BSA200 μ l, close for 4 DEG C and spend the night.Next day pats dry plank and does not wash plate.
3, monoclonal antibody hybridoma cell supernatant is added, each sample 8 micropores, every hole 50 μ l.37 DEG C, hatch 1h.
4, after washing plate 4 times, the rabbit anti-mouse igg 1, IgG2a, IgG2b, IgG3, IgA, IgM, κ, λ, 37 DEG C adding specific bond respectively hatches 1h.
5, after washing plate 4 times, every hole adds horseradish peroxidase-labeled anti-rabbit two anti-igg (H+L) of having diluted, and 37 DEG C, hatches 30min.
6, after washing plate 4 times, 100 μ l substrate nitrite ions are added, 37 DEG C, lucifuge colour developing 10min.Result is read under 450nm wavelength.
As shown in table 2, H3 belongs to IgG2a subclass, and G9 belongs to IgG1 subclass.
Table 2. liang strain monoclonal antibody subgroup identification result
Two, monoclonal antibody cross reaction test
1, antigen coated: by 96 kind 10
8the pathogenic bacteria of cfu/ml bacterial concentration join in ELISA Plate, and each pathogenic bacteria add 3 each holes, and every hole 100 μ l, wraps and spent the night by 4 DEG C.
2, close: after washing plate 3 times, every hole adds 3%BSA200 μ l, hatches 2h for 37 DEG C.
3, plate is washed 3 times.Every hole adds the monoclonal antibody 100 μ l diluted, and hatches 1h for 37 degrees Celsius.
4, plate is washed 3 times.Adding the goat against murine two of having diluted resists in all micropores, and every hole 100 μ l, hatches 1h for 37 degrees Celsius.
5, plate is washed 4 times.Add substrate nitrite ion, 37 DEG C, lucifuge colour developing 15min.Result is read under 450nm wavelength.
Table 3. liang strain monoclonal antibody cross reaction testing result
Embodiment 3. detects the composition of the enzyme linked immunological kit of campylobacter jejuni, preparation and application thereof
One, enzyme linked immunological kit is made up of following substances
(1) ELISA Plate of pre-coated antibody: wrap by 96 hole ELISA Plate with 0.02M acetate buffer solution (pH2.0) solution dilution, anti-campylobacter jejuni monoclonal antibody 3G2D8H3G9, every hole 100 μ l.4 DEG C of overnight incubation, conveniently ELISA method closes washing.
(2) campylobacter jejuni positive control standard items and negative control standard items.
(3) the monoclonal antibody 4C9E1G7H3 of the anti-campylobacter jejuni of horseradish peroxidase-labeled.
(4) enzyme labelled antibody dilution: 0.01MPBS, pH7.6.
(5) 10 × concentrated washing lotion: the 0.1M phosphate buffer containing 0.5% Tween-20 and 0.2% Sodium azide, pH7.4, dilutes concentrated washing lotion 10 times during use.
(6) nitrite ion A liquid, nitrite ion B liquid.Before using, A liquid is mixed with B liquid equal-volume.
(7) stop buffer: 2M sulfuric acid solution.
Two, the preparation of each component in enzyme linked immunological kit
(1) using campylobacter jejuni monoclonal antibody 3G2D8H3G9 as seizure antibody coated elisa plate
Be buffered liquid with bag and campylobacter jejuni monoclonal antibody 3G2D8H3G9 is diluted to 5 μ g/ml, every hole adds 100 μ l, 4 DEG C are spent the night, incline next day coating buffer, with the wash liquid diluted 3 times, pats dry, then in every hole, add 220 μ l confining liquids, 37 DEG C of incubation 2h, liquid in hole of inclining, preserves with aluminium foil bag sealing after drying.
Bag is buffered liquid: 0.02M acetate buffer solution, regulates pH to 2.0 with 5MHCl.
Confining liquid: the 0.01MPBS containing 0.3% bovine serum albumin(BSA) and 10% sucrose.
(2) preparation of the monoclonal antibody 4C9E1G7H3 of horseradish peroxidase-labeled
Campylobacter jejuni monoclonal antibody 4C9E1G7H3 and horseradish peroxidase (HRP) are carried out coupling, and the method for employing is the Over-voltage protection of improvement, and method is as follows:
A, 5mg horseradish peroxidase (HRP) is dissolved in 0.5ml0.2M acetate buffer solution (pH5.6).
B, add the 0.06MNaIO of existing preparation
4solution 0.5ml, 4 DEG C of oxidation 20min.
C, add 0.4M ethylene glycol solution 0.5ml containing 22%NaCl, room temperature leaves standstill 30min.
The absolute ethyl alcohol precipitation enzyme of d, use 6ml precooling, the centrifugal 10min of 1500rpm.
E, remove supernatant, precipitation is dissolved in the 0.01MPBS (pH7.4) of 2.5ml.
F, add 10mg monoclonal antibody 4C9E1G7H3, and use 0.5M carbonic acid buffer (pH9.6) to regulate pH to 9.0 immediately.4 DEG C of hold over night.
G, add 10mg/ml sodium borohydride 50 μ l, 4 DEG C, leave standstill 2h.
H, use 0.01MPBS (pH7.4) 4 DEG C of dialysed overnight.
I, purification storage.
Three, the application of kit
(1) detection method
1, sample pre-treatments
Get measuring samples 25g (ml) and add the homogeneous mixing under homogenizer of 225ml brucella broth, cultivate 16h for 36 DEG C ± 1 DEG C.Cultured sample is heated 10min in 100 DEG C of water-baths, and it is stand-by that taking-up is cooled to room temperature.
2, detect with kit
30min is placed under the micropore of taking-up requirement and all reagent normal temperature.Getting 200 μ l measuring samples is added in micropore, 37 DEG C, hatches 30min.Remove liquid in hole, add 200 μ l washing lotions in each micropore, rock the several seconds gently, fast upset is by liquid in micropore to the greatest extent, to a folded clean thieving paper clap several under, repeat operation and wash plate altogether 3 times.Add 100 μ l monoclonal antibody linked with peroxidase 4C9E1G7H3 working fluids, 37 DEG C, hatch 60min.Remove liquid in hole and wash plate 4 times.Colour developing A liquid and colour developing B liquid mixed in equal amounts are made into substrate nitrite ion.Each micropore adds the substrate nitrite ion of 100 μ l, room temperature lucifuge colour developing 15-20min.Add stop buffer 100 μ l, under 450nm, measure absorbance by microplate reader.
Result judges: negative control≤0.1, positive control >=0.3, and experimental result is effective, otherwise result be judged to be invalid; During detect aperture OD value >=0.2, be judged to be the positive; When detect aperture OD value is between 0.1-0.2, be judged to be the weak positive; Detect aperture OD value≤0.1 is judged to be feminine gender.
If without microplate reader, can with the naked eye judge: Positive control wells has macroscopic yellow, negative control hole is without color, and experimental result is effective, otherwise is judged to be that experimental result is invalid; Be positive findings when detect aperture has obvious macroscopic yellow; When having faint yellow, be judged to be weak positive findings; Without during naked eyes visible yellow color being negative findings.
(2) detection of enzyme linked immunological kit effect
1, kit repeatability and stability test
Precision test in plate: get 6 micropores in same ELISA Plate, test with the milk crossed by jejunum campylobacter fungi pollution, experiment repetition 4 times.
Precision test between plate: 4 pieces of ELISA Plate of getting same batch, tests with the milk crossed by jejunum campylobacter fungi pollution, experiment repetition 3 times.
The computing method of the coefficient of variation: the coefficient of variation (the CV)=standard deviation of measurement result and the number percent of its mean value.
Reperformance test result in table 4. plate
Reperformance test result between table 5. plate
2, kit cross reaction test
Go to detect other 91 kinds of food-borne pathogens and conventional food Carried bacteria with kit, whether checking kit detects the specificity of campylobacter jejuni, observe and have cross reaction and false positive to occur with other pathogenic bacteria.
Table 6. kit specificity is tested
Note: "+" represents that testing result is positive; "-" represents that testing result is negative.
3, kit storage life experiment
Kit preservation condition is 2-8 DEG C, and after 12 months, the testing result of kit is consistent with the kit results of new lot.Consider in transport and use procedure that having improper preservation condition occurs, placed 8 days under 37 DEG C of conditions of preserving by kit, carry out accelerated aging test, result shows that the indices of kit meets the requirements completely.Therefore kit at least can preserve more than 12 months at 2-8 DEG C.
The preservation of biomaterial
Produce and be preserved in (No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, China Committee for Culture Collection of Microorganisms's common micro-organisms center (CGMCC) through the hybridoma cell strain 3G2D8H3G9 of the campylobacter jejuni monoclonal antibody of above-mentioned qualification on January 9th, 2014, Institute of Microorganism, Academia Sinica, postcode: 100101), Classification And Nomenclature is " anti-campylobacter jejuni hybridoma ", and preserving number is CGMCCNo.8766.
Produce and be preserved in (No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, China Committee for Culture Collection of Microorganisms's common micro-organisms center (CGMCC) through the hybridoma cell strain 4C9E1G7H3 of the vibrio parahemolyticus monoclonal antibody of above-mentioned qualification on November 15th, 2013, Institute of Microorganism, Academia Sinica, postcode: 100101), Classification And Nomenclature is " anti-campylobacter jejuni hybridoma ", and preserving number is CGMCCNo.8457.
The all documents mentioned in the present invention are quoted as a reference all in this application, are just quoted separately as a reference as each section of document.In addition should be understood that those skilled in the art can make various changes or modifications the present invention, and these equivalent form of values fall within the application's appended claims limited range equally after having read above-mentioned instruction content of the present invention.
Claims (9)
1. a method for vitro detection campylobacter jejuni, described method is used for non-diseases diagnostic purpose, comprises the following steps:
A testing sample application of sample is caught the solid phase carrier of antibody in being coated with by (), thus the seizure antibody of the campylobacter jejuni in testing sample on solid phase carrier is combined, and forms the solid phase carrier with " campylobacter jejuni-seizure antibody " binary complex; Described seizure antibody is the monoclonal antibody 3G2D8H3G9 being incorporated into campylobacter jejuni specifically, and described monoclonal antibody 3G2D8H3G9 is produced by mouse hybridoma cell system 3G2D8H3G9, CGMCCNo.8766;
B () will detect the solid phase carrier that antibody application of sample obtains in (a), thus form the solid phase carrier with " detecting antibody-campylobacter jejuni-seizure antibody " ternary complex; Described detection antibody is the monoclonal antibody 4C9E1G7H3 being incorporated into campylobacter jejuni specifically, described monoclonal antibody 4C9E1G7H3 is by mouse hybridoma cell system 4C9E1G7H3, CGMCCNo.8457 produces, and described monoclonal antibody 4C9E1G7H3 carries a detectable; With
C () detects the detectable in ternary complex, thus whether and the amount existed the existence determining testing sample jejuni.
2. the method for claim 1, is characterized in that, described solid phase carrier is enzyme reaction plate.
3. the method for claim 1, is characterized in that, described detectable is horseradish peroxidase.
4. an immunoglobulin (Ig), it is the monoclonal antibody being incorporated into campylobacter jejuni specifically, it is characterized in that, it is by mouse hybridoma cell system 3G2D8H3G9, and CGMCCNo.8766 produced.
5. produce a hybridoma for monoclonal antibody, it is characterized in that, it is mouse hybridoma cell system 3G2D8H3G9, CGMCCNo.8766.
6. a purposes for immunoglobulin (Ig) as claimed in claim 4, is characterized in that, it is used to detect campylobacter jejuni, and described purposes is used for non-diseases diagnostic purpose.
7. an immunoglobulin (Ig), it is the monoclonal antibody being incorporated into campylobacter jejuni specifically, it is characterized in that, it is by mouse hybridoma cell system 4C9E1G7H3, and CGMCCNo.8457 produced.
8. produce a hybridoma for monoclonal antibody, it is characterized in that, it is mouse hybridoma cell system 4C9E1G7H3, CGMCCNo.8457.
9. a purposes for immunoglobulin (Ig) as claimed in claim 7, is characterized in that, it is used to detect campylobacter jejuni, and described purposes is used for non-diseases diagnostic purpose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510573715.0A CN105223363B (en) | 2015-09-10 | 2015-09-10 | The method of detection campylobacter jejuni and monoclonal antibody thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510573715.0A CN105223363B (en) | 2015-09-10 | 2015-09-10 | The method of detection campylobacter jejuni and monoclonal antibody thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105223363A true CN105223363A (en) | 2016-01-06 |
| CN105223363B CN105223363B (en) | 2016-08-24 |
Family
ID=54992431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510573715.0A Expired - Fee Related CN105223363B (en) | 2015-09-10 | 2015-09-10 | The method of detection campylobacter jejuni and monoclonal antibody thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105223363B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106556698A (en) * | 2016-12-05 | 2017-04-05 | 百奥森（江苏）食品安全科技有限公司 | A kind of campylobacter jejuni detection method |
-
2015
- 2015-09-10 CN CN201510573715.0A patent/CN105223363B/en not_active Expired - Fee Related
Non-Patent Citations (5)
| Title |
|---|
| HAROLD F.STILLS等: "Utilization of monoclonal antibodies to evaluate the involvement of Campylobacter jejuni in proliferative ileitis in Syrian hamsters.", 《INFECTION AND IMMUNITY》 * |
| 唐秋艳 等主编: "《免疫诊断试剂实用技术》", 31 August 2009 * |
| 姚楚铮 等: "抗空肠弯曲菌单克隆抗体某些免疫学特性的研究", 《中华传染病杂志》 * |
| 沈广 等: "单克隆抗体ELISA快速检测经济动物空肠弯曲菌的研究", 《特产研究》 * |
| 赵丽 等: "应用液相芯片检测空肠弯曲菌", 《中国动物检疫》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106556698A (en) * | 2016-12-05 | 2017-04-05 | 百奥森（江苏）食品安全科技有限公司 | A kind of campylobacter jejuni detection method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105223363B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104360065B (en) | Vibrio parahemolyticus enzyme-linked immunologic detecting kit | |
| CN103558388B (en) | Double-antibody sandwich method for detecting salmonella typhimurium in food based on monoclonal antibodies | |
| CN103792361B (en) | Enzyme-linked immunosorbent assay kit of enterohemorrhagic E.col O157:H7 | |
| CN104655847A (en) | Enzyme linked immunosorbent assay kit (ELISA kit) for detecting adprin and detection method thereof | |
| CN104316690A (en) | Rapid vibrio parahaemolyticus immune colloidal gold test strip | |
| CN103823062B (en) | Salmonella choleraesuls enzyme-linked immunologic detecting kit | |
| CN103940995B (en) | Listeria monocytogenes enzyme-linked immunologic detecting kit | |
| CN104360066B (en) | Detect method and the monoclonal antibody thereof of vibrio parahemolyticus | |
| CN103941011B (en) | Detect method and the monoclonal antibody thereof of listeria monocytogenes | |
| CN105223362A (en) | Campylobacter jejuni enzyme-linked immunologic detecting kit | |
| CN103777017B (en) | Detect method and the monoclonal antibody thereof of enterohemorrhagic Escherichia coli O 157: H7 | |
| CN103823063B (en) | Detect method and the monoclonal antibody thereof of Salmonella choleraesuls | |
| CN105223363B (en) | The method of detection campylobacter jejuni and monoclonal antibody thereof | |
| CN103913572B (en) | Method for detecting staphylococcus aureus and monoclonal antibodies of staphylococcus aureus | |
| CN103869074B (en) | Enzyme-linked immunoassay kit for staphylococcus aureus | |
| CN103820549B (en) | Salmonella choleraesuis immune PCR detection kit | |
| CN105132282B (en) | Campylobacter jejuni immuno-PCR detection kit | |
| CN105137075B (en) | Campylobacter jejuni immune colloid gold Rapid detection test strip | |
| CN103823060B (en) | Enterohemorrhagic Escherichia coli O 157: H7 immuno-PCR detection kit | |
| CN103937898B (en) | Listeria monocytogenes immuno-PCR detection kit | |
| CN103866033B (en) | Staphylococcus aureus immune PCR (polymerase chain reaction) detection kit | |
| CN114181909B (en) | Hybridoma cell strain, monoclonal antibody thereof and kit | |
| CN106596952A (en) | Salmonella cholerae enzyme-linked immunosorbent assay kit | |
| CN103941006B (en) | Salmonella choleraesuls immune colloid gold Rapid detection test strip | |
| CN103760311B (en) | Double-antibody sandwich method for detecting staphylococcus enterotoxin E in foods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |